Patent intelligence · US
US 10849891
Formulations of pimavanserin
Formulations of pimavanserin
Patent details — US 10849891
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 1, 2020
- Expiration
- Nov 26, 2040
- Applicant
- ACADIA Pharmaceuticals Inc.
- Claims
- 15
- CPC classes
- A61K, A61K31/4468, A61K47/38, A61K9/1652
Quick answer
US 10849891 (Formulations of pimavanserin) is held by ACADIA Pharmaceuticals Inc.. Status: granted. Granted Dec 1, 2020. Expires Nov 26, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ACADIA Pharmaceuticals Inc.
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K31/4468, A61K47/38, A61K9/1652, A61K9/1688, A61K9/1694
More from ACADIA Pharmaceuticals Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11844764
Agitation process for preparing a carbetocin drug product
granted -
US 11827600
Crystalline forms of trofinetide
granted -
US 11464768
Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease psychosis
granted -
US 11452721
Formulations of pimavanserin
granted -
US 11191757
Combination of pimavanserin and cytochrome P450 modulators
granted -
US 11161826
Manufacturing methods and polymorphs of a thiazoline anti-hyperalgesic agent
granted -
US 11135211
Pimavanserin for treating impulse control disorder
granted -
US 11091473
Compounds for pain treatment, compositions comprising same, and methods of using same
granted
Frequently asked questions
What is US patent 10849891?
US 10849891 (Formulations of pimavanserin) is held by ACADIA Pharmaceuticals Inc.. Status: granted. Granted Dec 1, 2020. Expires Nov 26, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10849891?
ACADIA Pharmaceuticals Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 77 pharmaceutical patents for this assignee.
When does US 10849891 expire?
Our index shows an expiration date of Nov 26, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.